About this trial
Cardiac surgery requires the use of extracorporeal circulation (ECC). Age-related differences in inflammatory response, the greater susceptibility of immature organ systems to injury and the larger ratio of extracorporeal circuitry to patient size make younger and smaller patients more vulnerable to organ injury. The main problem associated with ECC in neonates and infants is the duration of ECC due to heavier surgeries leading to a prolonged inflammatory state resulting in capillary leak syndrome, low cardiac output syndrome and organ dysfunction, resulting in higher morbidity and mortality. The means of limiting this inflammatory response remain limited. Future studies should aim to address new post-ECC prophylactic targets to improve myocardial and endothelial function. Cardiac metabolism is an important area of research because it plays a central role in maintaining cardiac function under stress. The study of O-GlcNAcylation could therefore be an interesting therapeutic target, given the beneficial role of its stimulation in acute stress situations, as demonstrated in sepsis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age from 0 to 17 years at the time of sampling
Children undergoing CEC for cardiac surgery
Signed bio-collection consent
Disqualifiers
Children with an infection
Children with fever
Children with an immune deficiency
Children with autoimmune disease
Trial population
Children aged between 0 and 17 undergoing cardiac surgery with extracorporeal circulation
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Evaluation of O-GlcNAcylation levels in cardiac surgery in children
To evaluate the evolution of O-GlcNAcylation levels in pre-per-post extracorporeal circulation in children
Secondary outcomes
Analysis of a potential link between O-GlcNAcylation levels and the prognosis of patients after cardiac surgery
To study the correlation between blood and cardiac O-GlcNAcylation levels and patient prognosis
Sponsors and contacts
Click on the lead sponsor to view all of their trials.